Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial

医学 冲程(发动机) 缺血性中风 内科学 随机对照试验 缺血 机械工程 工程类
作者
Bum Joon Kim,Eun‐Jae Lee,Sun U. Kwon,Jong‐Ho Park,Yong‐Jae Kim,Keun‐Sik Hong,Ka Sing Wong,Sungwook Yu,Yang‐Ha Hwang,Ji Sung Lee,Juneyoung Lee,Joung‐Ho Rha,Sung Hyuk Heo,Sung Hwan Ahn,Woo‐Keun Seo,Jong‐Moo Park,Ju-Hun Lee,Jee‐Hyun Kwon,Sung‐Il Sohn,Jin‐Man Jung
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:17 (6): 509-518 被引量:97
标识
DOI:10.1016/s1474-4422(18)30128-5
摘要

Background The optimal treatment for patients with ischaemic stroke with a high risk of cerebral haemorrhage is unclear. We assessed the efficacy and safety of cilostazol versus aspirin, with and without probucol, in these patients. Methods In this randomised, controlled, 2 × 2 factorial trial, we enrolled patients with ischaemic stroke with a history of or imaging findings of intracerebral haemorrhage or two or more microbleeds from 67 centres in three Asian countries. Patients were randomly assigned (1:1:1:1) to receive oral cilostazol (100 mg twice a day), aspirin (100 mg once a day), cilostazol plus probucol (250 mg twice a day), or aspirin plus probucol with centralised blocks stratified by centre. Cilostazol versus aspirin was investigated double-blinded; probucol treatment was open-label, but the outcome assessor was masked to assignment. The co-primary outcomes were incidence of the composite of stroke, myocardial infarction, or vascular death (efficacy) and incidence of haemorrhagic stroke (safety), which were assessed in intention-to-treat and modified intention-to-treat populations. Efficacy was analysed with a non-inferiority test and a superiority test if non-inferiority was satisfied. Safety was assessed with a superiority test only. This trial is registered with ClinicalTrials.gov, NCT01013532. Findings Between Aug 1, 2009, and Aug 31, 2015, we randomly assigned 1534 patients to one of the four study groups, of whom 1512 were assessed for the co-primary endpoints. During a median follow-up of 1·9 years (IQR 1·0–3·0), the incidence of composite vascular events was 4·27 per 100 person-years in patients who received cilostazol and 5·33 per 100 person-years in patients who received aspirin (HR 0·80, 95% CI 0·57–1·11; non-inferiority p=0·0077; superiority p=0·18). Incidence of cerebral haemorrhage was 0·61 per 100 person-years in patients who received cilostazol and 1·20 per 100 person-years in those who received aspirin (HR 0·51, 97·5% CI 0·20–1·27; superiority p=0·18). The incidence of vascular events was 3·91 per 100 person-years in the probucol group compared with 5·75 per 100 person-years in the non-probucol group (HR 0·69, 95% CI 0·50–0·97; superiority p=0·0316). The incidence of cerebral haemorrhage was 0·72 per 100 person-years in the probucol group and 1·11 per 100 person-years in the non-probucol group (HR 0·65, 97·5% CI 0·27–1·57; p=0·55). Adverse events were similar across the four study groups; the most common events were dizziness, headache, diarrhoea, and constipation. Interpretation In patients with ischaemic stroke at high risk of cerebral haemorrhage, cilostazol was non-inferior to aspirin for the prevention of cardiovascular events, but did not reduce the risk of haemorrhagic stroke. Addition of probucol to aspirin or cilostazol could be beneficial for reducing the incidence of cardiovascular events. Funding Korea Otsuka Pharmaceutical.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
wg发布了新的文献求助10
1秒前
pp发布了新的文献求助10
2秒前
bociic完成签到,获得积分10
3秒前
4秒前
4秒前
一人发布了新的文献求助10
5秒前
LiuShenglan发布了新的文献求助10
7秒前
香蕉觅云的应助被王光宇采纳,获得10
7秒前
秋风的应助被幕后编剧采纳,获得10
8秒前
科目三的应助被风-FBDD采纳,获得10
8秒前
strack完成签到,获得积分10
9秒前
Nole的应助被磕磕采纳,获得30
9秒前
10秒前
彭于晏的应助被dean采纳,获得10
10秒前
夜枭完成签到,获得积分10
10秒前
杨自强完成签到,获得积分10
11秒前
一朵云发布了新的文献求助10
11秒前
JamesPei的应助被一人采纳,获得10
12秒前
Xilli发布了新的文献求助10
13秒前
14秒前
heoouijee完成签到,获得积分20
15秒前
英吉利25发布了新的文献求助10
15秒前
科研通AI2S的应助被柳叶刀采纳,获得10
16秒前
汉堡包的应助被独特手机采纳,获得10
17秒前
体贴千山完成签到,获得积分10
18秒前
18秒前
NN的应助被hohn采纳,获得10
21秒前
shelter完成签到,获得积分10
22秒前
可爱的函函的应助被pp采纳,获得10
22秒前
22秒前
跳跃的谷秋完成签到,获得积分10
22秒前
科研通AI6.4的应助被斯南采纳,获得30
23秒前
23秒前
隐形晓夏完成签到,获得积分10
24秒前
25秒前
25秒前
隐形晓夏发布了新的文献求助10
26秒前
王英俊完成签到,获得积分10
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188634
求助须知:如何正确求助?哪些是违规求助? 9576342
关于积分的说明 21847026
捐赠科研通 7786653
什么是DOI,文献DOI怎么找? 3435402
关于科研通互助平台的介绍 2559632
邀请新用户注册赠送积分活动 2482360